Christina Rizopoulos Valauri
Christina Rizopoulos Valauri's purchase track record
Christina Rizopoulos Valauri has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/1/2026 | VBIO | $18K | -48.6% | +177.2% | +16.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Valion Bio Completes Oral Mucosal Entolimod Formulation. Valion Bio has successfully formulated an oral mucosal version of entolimod in partnership with Shear Kershman Laboratories. The company states this development could open a needle-free pathway and significantly expand its long-term opportunity. This news contributed to the stock appearing in pre-market movers, though the shares remain well below their 52-week high of $32.50.
Transaction History
| PRPO | ▲ Buy | Grant | 108 | $3K | 7/15/2026 | View on chart |
| PRPO | ▲ Buy | Grant | 93 | $3K | 4/15/2026 | View on chart |
| VBIO | ▲ Buy | Open Market | 19,000 | $18K | 4/1/2026 | View on chart |
| PRPO | ▲ Buy | Grant | 406 | $10K | 1/15/2026 | View on chart |
| PRPO | ▲ Buy | Grant | 1,472 | $10K | 10/15/2024 | View on chart |
| PRPO | ▲ Buy | Grant | 2,103 | $10K | 7/15/2024 | View on chart |
| PRPO | ▲ Buy | Grant | 1,446 | $10K | 4/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precipio Management Signals Growth, Institutions Take Interest
Precipio’s leadership outlined ambitious plans for future growth, drawing attention from institutional investors. The company’s strategy includes expanding its product line and entering new markets. Institutional involvement suggests confidence in the company’s direction. The move may influence investor sentiment and the stock’s short‑term activity.
Precipio Management Signals Growth, Institutions Take Interest. Precipio’s leadership outlined ambitious plans for future growth, drawing attention from institutional investors. The company’s strategy includes expanding its product line and entering new markets. Institutional involvement suggests confidence in the company’s direction. The move may influence investor sentiment and the stock’s short‑term activity.